About 858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology and neuroscience. Its programs focus on the emerging fields of synthetic lethality, innate immunity, and RNA modulation. The company's lead program is directed at PARG, which is a novel target in the DNA damage repair (DDR) pathway, and is scheduled to begin a phase 1 trial in 2024.
858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in oncology and drug development, 858 scientists are dedicated to the company's mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.
858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in San Diego, providing proximity to leading investigators and scientific talent.
3115 Merryfield Row, Suite 110
San Diego, CA 92121